Real-world treatment outcomes of abemaciclib in older patients with HR+, HER2- metastatic breast cancer in Japan.

ABSTRACT:

Aim

To understand the real-world use of abemaciclib in older patients (≥65 years) with HR+, HER2- metastatic breast cancer (MBC) in Japan.

Methods

This study retrospectively analyzed a Japanese administrative claims database for patients with HR+, HER2- MBC who received abemaciclib as the first CDK4/6 inhibitor (CDK4/6i) from November 2018 to May 2023. Patient characteristics and treatment patterns were summarized. Median time to discontinuation (mTTD) and chemotherapy-free survival (CSF) was estimated using Kaplan - Meier method.

Results

Among 3,699 abemaciclib-treated patients with HR+, HER2- MBC, 1,681 (45.4%) were ≥65 years old. Among these, abemaciclib + fulvestrant (55.0%) was the most common regimen. The mTTD (95% CI) of first abemaciclib therapy was 12.8 month

SUBMITTER: Shimoi T 

PROVIDER: S-EPMC12520067 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature